Thymosin Alpha 1 (Ta1)

Overview

Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.

Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

FDA orphan designation for DiGeorge syndrome; restores T-cell function.

Improved antibody responses in elderly and hemodialysis patients (H1N1, COVID-19).

Restores CD4+ counts and reduces opportunistic infections.

Reduces pro-inflammatory cytokines TNF-α, IL-1β, IL-6 by 40-60%.

Mechanism

Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.

Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

FDA orphan designation for DiGeorge syndrome; restores T-cell function.

Research areas

• Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.
• Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.
• FDA orphan designation for DiGeorge syndrome; restores T-cell function.
• Improved antibody responses in elderly and hemodialysis patients (H1N1, COVID-19).
• Restores CD4+ counts and reduces opportunistic infections.
• Reduces pro-inflammatory cytokines TNF-α, IL-1β, IL-6 by 40-60%.
• Enhanced antiviral efficacy when combined with interferon.
• Helps manage inflammatory autoimmune conditions.
• Restores immune function after surgical stress.
• Manages immune suppression from intense training.
• Supports thymus gland function with aging.
• Delays age-related immune decline in elderly populations.

Research notes

• Mild injection site reactions (<10% incidence)
• Generally well-tolerated with exceptional safety record
• Signs of graft rejection in transplant recipients
• Persistent injection site reactions or infection signs
• Unusual immune system hyperactivity
• Severe allergic reactions (rare)
• Organ transplant recipients (risk of graft rejection)
• Pregnancy and breastfeeding
• Injectable has 90-95% bioavailability versus nasal spray's 40-60%. Injectable is the primary FDA-studied route with most clinical validation. Nasal spray may work for local immune effects but requires compounding pharmacy preparation and shows lower systemic absorption - inject for maximum efficacy.

Pharmacokinetics

• Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

References

• pubmed.ncbi.nlm.nih.gov/38308608/
• pubmed.ncbi.nlm.nih.gov/32442287/
• pubmed.ncbi.nlm.nih.gov/39814420/
• pubmed.ncbi.nlm.nih.gov/17567941/

FAQs